The term micromegaly has been used to describe a subset of patients who have elevated IGF-1 levels but apparently normal basal GH (bGH) concentrations and often a glucose-suppressed GH of ,1 ng/mL.
A ccording to the most recent consensus guidelines, acromegaly can be confidently diagnosed when a patient with the classic symptoms and signs of the disease shows an elevated age-adjusted IGF-1 concentration and a lack of suppression of GH levels ,1 ng/mL after administration of an oral glucose load (1, 2) . Most patients also have an elevated basal GH (bGH) concentration, sometimes reaching $100 ng/mL (1, 2) . The term micromegaly has been used to describe a subset of patients with clinically evident acromegaly who upon biochemical evaluation have elevated age-adjusted IGF-1 levels but apparently normal bGH concentrations and often a glucose-suppressed GH of ,1 ng/mL (3). The term was initially coined by Dimaraki et al. (3) , who, in 2002, reported 16 patients with these characteristics. Although a few reports have been published since then, describing such an apparently discrepant biochemical scenario, controversy still exists regarding its true prevalence, in part because of the different criteria used to define a normal basal and glucose-suppressed GH level (4) (5) (6) (7) (8) . Whereas some of these series consider as normal a serum GH level #4.7 ng/mL (3, 7, 8) , others use much lower cutoffs such as 2.5 ng/mL (4, 5, 7) .
Little is known about the clinical behavior and therapeutic outcomes of these patients, because most published studies focus mainly on the biochemical description of the phenomenon. It is not clear whether this condition is a distinct clinical entity or is simply classic acromegaly diagnosed in its early stages. To establish the real prevalence and clinical spectrum of micromegaly, we analyzed a large cohort of patients with acromegaly followed at our institution for .17 years.
Patients and Methods
We evaluated patients diagnosed, treated, and followed at the Endocrinology Service of Hospital de Especialidades, Centro Médico Nacional Siglo XXI, Instituto Mexicano del Seguro Social from 1990 to 2017. The main inclusion criterion was the availability of full clinical and biochemical information obtained at our hospital before any treatment. Clinical information included the presence of acromegalic symptoms, signs, and comorbidities. Biochemical information consisted of basal and glucose-suppressed GH levels as well as serum IGF-1 concentrations at diagnosis and 6 months after surgical resection of the pituitary adenoma. All patients signed the appropriate informed consent, and the protocol was approved by our local ethics and scientific committees.
Definitions
Data regarding symptoms and signs of acromegaly and GH and IGF-1 measurements were collected directly from the patient's chart. Acromegaly was diagnosed based on the finding of a glucose-suppressed GH .1 ng/mL and an IGF-1 .1.2 times above the upper limit of normal (ULN) in a patient with the classic symptoms and signs of the disease. A bGH ,2 ng/mL was considered normal. In most operated patients, the diagnosis was confirmed by a positive GH immunohistochemistry of the adenoma. Diabetes mellitus was defined as the presence of fasting hyperglycemia $126 mg/dL or a blood glucose level $200 mg/dL 120 minutes after a 75-g glucose load. Hypertension was considered to be present if the systolic or diastolic values exceeded 140 and 90 mm Hg, respectively. Postoperative remission was evaluated 6 months after pituitary surgery and defined by an IGF-1 level ,1.2 3 ULN.
Hormonal measurements
From 1990 to 1999 GH was measured with a polyclonal RIA, with a detection limit of 0.7 ng/mL and intra-assay and interassay of coefficient of variation (CV) of 10% (Diagnostic Products Corporation, Los Angeles, CA); this RIA uses as calibrator the standard preparation 80/505 of pituitary origin. From 2000 to 2007, GH was measured by means of the Immulite two-site chemiluminescent assay (Diagnostic Products Corporation, Los Angeles, CA), with a sensitivity of 0.01 ng/mL and intra-assay and interassay CVs of 6%. As of 2008, GH has been determined with the DiaSorin Liaison assay (Saluggia, Italy), which has a detection limit of 0.009 ng/mL and intraassay and interassay CVs of 2.5% and 5.8%, respectively. The international reference preparation used in these GH assays is the World Health organization second 95/574. IGF-1 was separated from its binding proteins by acidethanol extraction before immunoassay. From 1990 to 1995, we used the Nichols RIA. From 1996 to 2007, we used the Diagnostic Systems Laboratory two-site chemiluminescent assay (DSL, Webster, TX) with intra-assay and interassay CVs of 2.6% and 4.4%, respectively. Since 2008 IGF-1 has been determined by the DiaSorin Liaison chemiluminescent assay (Saluggia, Italy). The international reference preparation in these IGF-1 assays is the World Health Organization second 02/254. We established our own normative IGF-1 data by analyzing serum samples from 400 healthy adults aged 18 to 75 years.
Statistical analysis
Quantitative variables are expressed as medians along with interquartile ranges (IQRs) because of their nonnormal distribution. Data distribution was determined by means of the Shapiro-Wilk test. Proportions and frequencies were used for categorical variables. Differences in categorical variables between groups were analyzed by x 2 test or Fisher exact test. Kruskal-Wallis test was used to identify differences between groups according to the level of bGH. The Wilcoxon rank test was used to evaluate differences between the group with the minimal and maximal bGH levels (,2 ng/mL or .100 ng/mL) and the other groups. P , 0.05 was considered statistically significant. Statistical analyses were performed in SPSS version 16.5 (SPSS, Chicago, IL).
Results
From a total cohort of 528 patients with acromegaly diagnosed, treated, and followed at our center we identified a subgroup of 16 subjects (3%), 7 women and 9 men, whose bGH at diagnosis was ,2 ng/mL, along with an elevated age-matched IGF-1 level (Table 1) . We compared their clinical, biochemical, tumoral, and treatment outcome characteristics with those of the remaining 512 patients whose bGH at diagnosis was .2 ng/mL. The total cohort was stratified as follows: group 1, normal bGH ,2 ng/mL, n = 16; group 2, bGH 2 to 9.9 ng/mL, n = 202; group 3, bGH 10 to 99 ng/mL, n = 294; and group 4, bGH $100 ng/mL, n = 16.
Patients in group 1 were significantly older (median age 54 years, IQR 51 to 59) than patients in the other three groups (Table 2) . Furthermore, median age decreased progressively as bGH at diagnosis increased, from 48 years (IQR 40 to 58) in group 2, to 40.5 years (IQR 25.3 to 75) in group 3, to 36 years (IQR 27.5 to 44) in group 4 ( Table 2) . Although there was a slight male predominance among patients in group 1 (56.3%), sex distribution progressively favored women over men in the other groups as bGH at diagnosis increased (percentage female: group 2, 65%; group 3, 59%; group 4, 81%). (Table 2 ). Patients in group 1 had an estimated mean diagnostic delay of 5 years (IQR 3.5 to 9.5), which did not differ significantly from that found in the other groups (5 years, IQR 3 to 8).
From a clinical standpoint, the frequency of acromegalic symptoms and signs such as acral growth, headache, fatigue, hyperhidrosis, arthralgia, and snoring was similar between groups (Table 2) . Although patients in group 1 tended to have a higher prevalence of hypertension and patients in group 4 seemed to have a higher prevalence of diabetes, neither of these observations reached statistical significance (Table 2) .
Median postglucose GH levels were significantly lower among patients in group 1 and increased progressively in the other three groups, as bGH increased (Table 3) . Whereas all patients in groups 2, 3, and 4 had glucose-suppressed GH levels .1 ng/mL, 9 out of 16 patients in group 1 (56%) were capable of suppressing their GH levels to ,1 ng/mL upon glucose loading; furthermore, 3 of the 16 patients (18.7%) had nadir postglucose GH levels ,0.4 ng/mL (Table 3) . Median total IGF-1 concentrations were significantly lower among group 1 patients and tended to increase progressively along with bGH (Table 3) . When adjusted by age, IGF-1 3 ULN was also significantly lower among patients in group 1 than in the other three groups. IGF-1 3 ULN did not differ significantly between patients in groups 2, 3, and 4 ( Table 2 ). The majority of patients (75%) in group 1 harbored microadenomas. However, as bGH at diagnosis increased, the proportion of patients with microadenomas progressively decreased to the point that all patients in group 4 harbored macroadenomas (Table 3) .
Of the 16 patients with normal bGH acromegaly, 13 underwent transsphenoidal resection of their pituitary adenomas. Of these 13 patients, one died before he could (Fig. 1) . Eight of the 16 patients with normal bGH were treated with somatostatin analogs, as primary treatment in 3 patients and as adjunctive treatment after failed pituitary surgery in 5 patients (Table 1) . Biochemical control was attained in 3 of these 8 pharmacologically treated patients (2 on primary and 1 on secondary treatment).
Discussion
In normal physiology, .75% of the GH secreted by the pituitary gland is released in pulses that occur mostly during the night (9) . Such pulsatile secretion is distorted in the acromegalic state, whereby a large proportion of the GH secreted by the adenoma is released in a nonpulsatile fashion (10) . Thus, the majority of patients with acromegaly have significantly elevated bGH levels that do not suppress upon glucose administration (10) . The definition of what constitutes a normal basal and glucose-suppressed GH has evolved in parallel with the development of GH immunoassays (11) . Old GH RIAs used to have detection limits between 0.7 and 1 ng/mL, and because they used polyclonal antibodies they could not only detect the predominant monomeric 22-kDa GH isoform but also cross-react with other molecular forms such as the 20-kDa isoform and with dimeric and deamidated variants (12) (13) (14) . These RIAs used nonrecombinant calibrators obtained from human pituitaries, containing GH molecular variants other than the 22-kDa isoform, and thus yielded readings higher than those obtained with the currentlyin-use ultrasensitive monoclonal immunoassays, which are calibrated against recombinant reference preparations made of exclusively 22-kDa GH (12) (13) (14) . In the 1970s and 1980s, when all analytical methods for GH measurement were polyclonal RIAs, a bGH of ,10 ng/mL and a glucose-suppressed GH of ,2 ng/mL were considered normal (12) (13) (14) . With the emergence of the monoclonal ultrasensitive assays that have detection limits as low as 0.001 ng/mL, we now know that a normal person should suppress her or his GH to ,0.4 ng/mL or even to ,0.2 ng/mL upon glucose loading and that normal bGH levels are usually ,4 ng/mL or even 2 ng/mL, depending on whether they derive from a random fasting sample or from the mean of several samples obtained over a variable number of hours (4, (15) (16) (17) . Our study demonstrates that in real life, acromegaly with normal bGH is a rare event, because only 3% of patients in our cohort presented with such a biochemical picture. Although our results coincide with those of Machado et al. (6) , they are in sharp contrast to the findings reported in three studies from the University of Michigan group, who reported micromegaly in 25% to 30% of their population of patients with acromegaly (3, 7, 8) . This discrepancy can be explained at least in part by the cutoff levels used to define a normal GH in those three studies (3, 7, 8) . Whereas in our study we defined as normal a bGH ,2 ng/mL, the three studies from the University of Michigan used GH cutoffs of 5, 4.7, and 4.3 ng/mL, respectively, apparently based on the mean 24-hour GH profile they found in healthy controls (3) . We chose the 2-ng/mL cutoff based on published data derived from 213 healthy individuals with normal ageadjusted IGF-1 concentrations in whom GH, measured by three different ultrasensitive immunoassays, was below this level (17) . Three different GH assays were used over the period of time covered by the study, and we acknowledge that this by itself constitutes a limitation for interpreting our results. However, in almost 90% of the cohort (464 patients) GH was measured with two well-validated monoclonal GH immunoassays with similar detection limits and CVs and calibrated against the same recombinant international reference preparation.
Pathophysiologically, it is not clear whether patients with acromegaly with normal bGH levels at diagnosis constitute a distinct clinical entity or simply have classic acromegaly detected in its early stages. The fact that most of our patients with micromegaly were older, harbored microadenomas, and yet had a similar disease duration and a similar clinical course to patients with elevated bGH at diagnosis supports the hypothesis that this is an entity with a distinct biological behavior characterized by a low GH output. Previously published studies on the subject have focused mainly on the biochemical characteristics of these patients (3, 4, (6) (7) (8) , whereas ours compares their clinical features with those of patients with elevated bGH. In this regard, we have shown that patients with normal bGH have the same frequency of acromegalic symptoms, signs, and comorbidities, which also indicates that this is not earlyonset disease.
As previously shown by others, our patients with normal bGH at diagnosis had lower nadir postglucose GH concentrations than those who presented with an elevated bGH (4, (6) (7) (8) . In fact, more than half of them could suppress their GH concentrations to ,1 ng/mL after glucose administration. Even though all our patients with normal bGH had elevated age-adjusted IGF-1 concentrations, the degree of elevation was significantly lower than that found in patients with elevated bGH. This finding has been reported before and suggests that patients with micromegaly have a biochemically milder form of acromegaly, which does not translate into a clinically less severe disease. Regarding the therapeutic outcomes of these patients, our data show that the surgical remission rate (defined by the achievement of IGF-1 levels ,1.2 3 ULN) is the same as that found in patients with acromegaly and an elevated bGH at diagnosis, when evaluated 6 months postoperatively.
We conclude that normal bGH acromegaly or micromegaly is uncommon among patients with acromegaly. Some distinctive features of these patients such as being older and more often male, harboring small, noninvasive adenomas, and having lower IGF-1 and postglucose GH levels, and yet the same frequency and severity of clinical signs and comorbidities as patients with classic acromegaly, argue against the hypothesis that this is simply acromegaly in its early stages.
